Search Results

You are looking at 101 - 110 of 2,641 items for :

  • Refine by Access: All x
Clear All
Full access

Hinda Boutrid, Maryam Lustberg, Jeffrey Vandeusen, Sagar Sardesai, Daniel Stover, Robert Wesolowski, Mathew Cherian, Julie Stephens, Marilly Palettas, Evan Morgan, Mohmoud Kassem, Michael Berger, Craig A. Vargo, Bhuvaneswari Ramaswamy, and Nicole Williams

outcomes and treatment strategies of metastatic ILC. This retrospective study evaluates the overall survival (OS) and progression-free survival (PFS) in the metastatic ILC population at a single institution, focusing on first line treatment received in the

Full access

Bin Wu and Lizheng Shi

gemcitabine-based chemotherapy, has significantly improved the outcome of patients with metastatic pancreatic cancer (MPC), increasing median overall survival (OS) to 8 to 12 months. 3 However, therapeutic options for MPC are still limited and the prognosis

Full access

Ali A. Mokdad, Amit G. Singal, Jorge A. Marrero, Hao Zhu, and Adam C. Yopp

for HCC remains below 20% in the United States. 2 Poor HCC outcomes are largely attributed to low rates of HCC surveillance and high rates of late stage diagnosis. 3 , 4 Accurate HCC staging is important for patient prognostication, treatment

Full access

Joseph A. Greer, Jamie M. Jacobs, Nicole Pensak, Lauren E. Nisotel, Joel N. Fishbein, James J. MacDonald, Molly E. Ream, Emily A. Walsh, Joanne Buzaglo, Alona Muzikansky, Inga T. Lennes, Steven A. Safren, William F. Pirl, and Jennifer S. Temel

survival. 10 – 14 Despite its importance for optimal outcomes, adherence to these medications varies widely, with rates ranging from as high as 100% to <50%. 15 – 18 A variety of patient-, clinician-, treatment-, and healthcare system–related factors are

Full access

Christina Signorelli, Claire E. Wakefield, Karen A. Johnston, Joanna E. Fardell, Jordana K McLoone, Mary-Ellen E. Brierley, Maria Schaffer, Elysia Thornton-Benko, Afaf Girgis, W. Hamish Wallace, Richard J. Cohn, and on behalf of the BSU Implementation Group

increasingly recognized as key health professionals in survivorship care delivery, with preliminary evidence suggesting that nurse-led care is safe, acceptable, and feasible. 7 Specialized nurse practitioners have the potential to optimize patient outcomes by

Full access

Quisette P. Janssen, Jacob L. van Dam, Laura R. Prakash, Deesje Doppenberg, Christopher H. Crane, Casper H.J. van Eijck, Susannah G. Ellsworth, William R. Jarnagin, Eileen M. O’Reilly, Alessandro Paniccia, Marsha Reyngold, Marc G. Besselink, Matthew H.G. Katz, Ching-Wei D. Tzeng, Amer H. Zureikat, Bas Groot Koerkamp, Alice C. Wei, and for the Trans-Atlantic Pancreatic Surgery (TAPS) Consortium

pathologic outcomes were collected locally and merged after deidentification. OS was defined from date of tissue diagnosis to date of death, with censoring at the date of last follow-up for patients with no event. The date of final analysis for the cohort was

Full access

Praveen Adusumilli, Vidya Viswanath, and Raghunadha Rao Digumarthi

Introduction: Perception of pain and the need to treat it is highly variable, even amongst oncologists. Availability of pain specialists is an added advantage. This is an analysis of prescription patterns of pain medication and its outcome in

Full access

Vinayak Muralidhar, Paul L. Nguyen, Brandon A. Mahal, David D. Yang, Kent W. Mouw, Brent S. Rose, Clair J. Beard, Jason A. Efstathiou, Neil E. Martin, Martin T. King, and Peter F. Orio III

focused on receipt of locoregional treatment, compared with others with N0M0 disease, node-positive disease, or metastatic disease. We also studied survival outcomes among these various subgroups of patients and explored the possible survival benefit

Full access

Paul D. Harker-Murray, Lauren Pommert, and Matthew J. Barth

-rituximab era, risk-stratified, response-based, multiagent chemotherapy included higher doses and additional cycles of chemotherapy for patients with higher-stage disease and resulted in cure rates ranging from 79% to 98% ( Table 1 ). Table 1. Outcomes for

Full access

Jeffrey S. Dome, Elizabeth A. Mullen, David B. Dix, Eric J. Gratias, Peter F. Ehrlich, Najat C. Daw, James I. Geller, Murali Chintagumpala, Geetika Khanna, John A. Kalapurakal, Lindsay A. Renfro, Elizabeth J. Perlman, Paul E. Grundy, and Conrad V. Fernandez

lack of lymph node sampling. AREN0532 demonstrated an excellent outcome with a high salvage rate for patients with disease relapse using a standardized regimen (DD4A; doxorubicin/vincristine/dactinomycin) and radiation therapy (RT) ( Table 2 ). 8 A